April 21, 2024

The Global Antiplatelet Drugs Market Is Propelled By Rising Geriatric Population And Increasing Prevalence Of Cardiovascular Diseases

Antiplatelet drugs are medications that are used to inhibit platelet activation and reduce thrombosis or formation of blood clots inside the blood vessels. Some common antiplatelet drugs include aspirin, clopidogrel, prasugrel, ticagrelor etc. These are mainly used for decreasing the risk of heart attacks and strokes in patients suffering from atherosclerosis, myocardial infarction or unstable angina.

The global Antiplatelet Drugs Market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising geriatric population across the globe is the major driver boosting the growth of antiplatelet drugs market. As per the United Nations report, the number of people aged 60 years or above is projected to grow from 962 million globally in 2017 to 2.1 billion by 2050. With increasing age comes greater health challenges like cardiovascular diseases. Moreover, unhealthy lifestyle choices such as rising tobacco consumption, physical inactivity, and poor diet have led to a rise in incidences of cardiovascular diseases worldwide. This has significantly increased the demand for effective antiplatelet drugs to reduce the risks of heart attacks and strokes. Hence, the growing prevalence of cardiovascular diseases among the growing geriatric population will augment the demand for antiplatelet drugs market during the forecast period.

SWOT Analysis

Strength: Antiplatelet drugs are effective in reducing complications in various cardiovascular diseases. Their effectiveness in reducing platelet aggregation helps prevent thrombosis.

Weakness: Antiplatelet drugs increase the risk of bleeding as they interfere with the body’s natural clotting mechanism. They require careful dosage management.

Opportunity: Rising prevalence of cardiovascular diseases and increasing awareness about antiplatelet therapy present an opportunity for market growth. Growing geriatric population prone to such conditions also provides opportunities.

Threats: Patent expiries of major drug brands open up the market for generics, impacting prices and market share of leading players. Stringent regulatory norms for new drug approvals also act as a threat.

Key Takeaways

The global antiplatelet drugs market demand is expected to witness high growth. The global Antiplatelet Drugs Market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.

The North America region currently dominates the antiplatelet drugs market owing to high awareness about cardiovascular health, developed healthcare infrastructure and large patient pool. However, the Asia Pacific region is expected to grow at the fastest pace owing to increasing healthcare expenditure, rising cardiac patient numbers and growing medical tourism.

Key players related content comprises

Key players operating in the antiplatelet drugs market are Chang Chun Group, Covestro AG, Dow and Hexio. Leading antiplatelet drugs from these manufacturers include clopidogrel, prasugrel, ticagrelor and ticlopidine. The market remains competitive with these players focusing on product innovation, portfolio expansion and marketing strategies to strengthen their market position

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it